Key Takeaways
- Cibus reported a net loss of $49.4M for Q1 2025, mainly due to a $21M goodwill impairment
- USDA, California, and Ecuador issued favorable regulatory decisions on Cibus’ gene-edited crops
- Rice, canola, and soybean programs advanced toward commercialization
- Cash runway expected through Q3 2025
- Strategic alternatives under review
Cibus CEO Highlights Global Momentum
“With our RTDS® platform now delivering results in under 12 months, we’re entering a new phase of commercial readiness,” said Peter Beetham, Co-Founder, Interim CEO, President and COO of Cibus.
Cibus Trait Development Progress and Commercial Milestones
Weed Management Traits in Rice
- Cibus’ HT1 and HT3 herbicide tolerance traits are being field-tested in stacked configurations
- Four rice partnerships active, including with FEDEARROZ
- Trait delivery to customers in California and Latin America expected in 2025
Canola Sclerotinia Resistance Advances
- Third mode of action confirmed in greenhouse data (March 2025)
- Fourth mode of action edited in November 2024; field trials planned for 2025
- Collaboration with Biographica enhances trait discovery using AI
Sustainable Ingredients Program
- Ongoing development of a fermentation-based biofragrance
- Commercial plans in progress with CPG partner
Cibus Expands Platform Capabilities Across Crops
Soybean Platform Update
- HT2 trait successfully edited in soybean cells (January 2025)
- Platform development expanding toward full plant trait delivery
RTDS Platform Standardization
- Production standards established for gene edits in rice and canola
- Targeted trait delivery timeline: under 12 months
Global Regulatory Recognition for Cibus Traits
United States
-
USDA-APHIS designated two canola traits as “not regulated” (April 2025)
California
-
State’s first gene-edited rice trial approved (February 2025)
Ecuador
-
HT1 and HT3 rice traits determined to be equivalent to conventional breeding (April 2025)
European Union
-
Council approved mandate for NGT regulation trilogue discussions (March 2025)
Outlook: Cibus Targets Key Milestones in 2025
Rice
- Expanded partnerships and commercial engagement in the Americas
- Field trials and trait deliveries expected in California and Latin America
Soybean
-
Full plant HT2 trait edits targeted for 2025
Canola
- Field testing for third and fourth Sclerotinia resistance modes
- Early greenhouse results from fourth mode due in Q2
Sustainable Ingredients
- Revenue expected in 2025 from biofragrance commercialization
- Continued development with global CPG partner
Cibus Q1 2025 Financial Overview
Consolidated Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Net Loss | $49.4M | $27.0M | +$22.4M |
| R&D Expense | $11.8M | $12.0M | -$0.2M |
| SG&A Expense | $9.9M | $7.0M | +$2.9M |
| Goodwill Impairment | $21.0M | $0 | +$21.0M |
| Cash Position | $23.6M | N/A | Sufficient into Q3 |
| Net Loss Per Share (Class A) | $1.34 | $1.12 | +$0.22 |
Management Comments on Financials
- Non-cash goodwill impairment of $21M due to lower stock price
- SG&A increase driven by estimated litigation liability
- Cost-saving efforts underway to preserve liquidity
- No revenue recorded in Q1 2025; commercialization still in early stages
Strategic Update: Cibus Evaluates Growth Options
Cibus continues to explore strategic alternatives with its financial advisors to maximize shareholder value. The company reaffirmed its commitment to disciplined execution and advancing regulatory, technical, and commercial progress in 2025.
Read the company’s financial results here.
1 Comment